410 ILCS 710/ Overdose Prevention and Harm Reduction Act.

Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process. Recent laws may not yet be included in the ILCS database, but they are found on this site as Public Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the Guide.

Because the statute database is maintained primarily for legislative drafting purposes, statutory changes are sometimes included in the statute database before they take effect. If the source note at the end of a Section of the statutes includes a Public Act that has not yet taken effect, the version of the law that is currently in effect may have already been removed from the database and you should refer to that Public Act to see the changes made to the current law.

410 ILCS 710/1

(410 ILCS 710/1)

Sec. 1. Short title. This Act may be cited as the Overdose Prevention and Harm Reduction Act.

(Source: P.A. 101-356, eff. 8-9-19.)

410 ILCS 710/5

    (410 ILCS 710/5)
    (Text of Section before amendment by P.A. 103-980)
    Sec. 5. Needle and hypodermic syringe access program.

(a) Any governmental or nongovernmental organization, including a local health department, community-based organization, or a person or entity, that promotes scientifically proven ways of mitigating health risks associated with drug use and other high-risk behaviors may establish and operate a needle and hypodermic syringe access program. The objective of the program shall be accomplishing all of the following:

(1) reducing the spread of HIV, AIDS, viral

hepatitis, and other bloodborne diseases;

(2) reducing the potential for needle stick injuries

from discarded contaminated equipment; and

(3) facilitating connections or linkages to

evidence-based treatment.

    (b) Programs established under this Act shall provide all of the following:
        (1) Disposal of used needles and hypodermic syringes.
        (2) Needles, hypodermic syringes, and other safer

drug consumption supplies, at no cost and in quantities sufficient to ensure that needles, hypodermic syringes, or other supplies are not shared or reused.

        (3) Educational materials or training on:
            (A) overdose prevention and intervention; and
            (B) the prevention of HIV, AIDS, viral hepatitis,

and other common bloodborne diseases resulting from shared drug consumption equipment and supplies.

(4) Access to opioid antagonists approved for the

reversal of an opioid overdose, or referrals to programs that provide access to opioid antagonists approved for the reversal of an opioid overdose.

(5) Linkages to needed services, including mental

health treatment, housing programs, substance use disorder treatment, and other relevant community services.

(6) Individual consultations from a trained employee

tailored to individual needs.

(7) If feasible, a hygienic, separate space for

individuals who need to administer a prescribed injectable medication that can also be used as a quiet space to gather composure in the event of an adverse on-site incident, such as a nonfatal overdose.

(8) If feasible, access to on-site drug adulterant

testing supplies.

(c) Notwithstanding any provision of the Illinois Controlled Substances Act, the Drug Paraphernalia Control Act, or any other law, no employee or volunteer of or participant in a program established under this Act shall be charged with or prosecuted for possession of any of the following:

(1) Needles, hypodermic syringes, or other drug

consumption paraphernalia obtained from or returned, directly or indirectly, to a program established under this Act.

(2) Residual amounts of a controlled substance

contained in used needles, used hypodermic syringes, or other used drug consumption paraphernalia obtained from or returned, directly or indirectly, to a program established under this Act.

(3) Drug adulterant testing supplies obtained from or

returned, directly or indirectly, to a program established under this Act or a pharmacy, hospital, clinic, or other health care facility or medical office dispensing drug adulterant testing supplies in accordance with Section 10. This paragraph also applies to any employee or customer of a pharmacy, hospital, clinic, or other health care facility or medical office dispensing drug adulterant testing supplies in accordance with Section 10.

(4) Any residual amounts of controlled substances

used in the course of testing the controlled substance to determine the chemical composition and potential threat of the substances obtained for consumption that are obtained from or returned, directly or indirectly, to a program established under this Act. This paragraph also applies to any person using drug adulterant testing supplies procured in accordance with Section 10 of this Act.

In addition to any other applicable immunity or limitation on civil liability, a law enforcement officer who, acting on good faith, arrests or charges a person who is thereafter determined to be entitled to immunity from prosecution under this subsection (c) shall not be subject to civil liability for the arrest or filing of charges.

(d) Prior to the commencing of operations of a program established under this Act, the governmental or nongovernmental organization shall submit to the Illinois Department of Public Health all of the following information:

(1) the name of the organization, agency, group,

person, or entity operating the program;

(2) the areas and populations to be served by the

program; and

(3) the methods by which the program will meet the

requirements of subsection (b) of this Section.

    The Department of Public Health may adopt rules to implement this subsection.
(Source: P.A. 101-356, eff. 8-9-19; 102-1039, eff. 6-2-22.)

    (Text of Section after amendment by P.A. 103-980)
    Sec. 5. Needle and hypodermic syringe access program.

(a) Any governmental or nongovernmental organization, including a local health department, community-based organization, or a person or entity, that promotes scientifically proven ways of mitigating health risks associated with drug use and other high-risk behaviors may establish and operate a needle and hypodermic syringe access program. The objective of the program shall be accomplishing all of the following:

(1) reducing the spread of HIV, AIDS, viral

hepatitis, and other bloodborne diseases;

(2) reducing the potential for needle stick injuries

from discarded contaminated equipment; and

(3) facilitating connections or linkages to

evidence-based treatment.

drug consumption supplies, at no cost and in quantities sufficient to ensure that needles, hypodermic syringes, or other supplies are not shared or reused.

        (3) Educational materials or training on:
            (A) overdose prevention and intervention; and
            (B) the prevention of HIV, AIDS, viral hepatitis,

and other common bloodborne diseases resulting from shared drug consumption equipment and supplies.

(4) Access to opioid antagonists approved for the

reversal of an opioid overdose, or referrals to programs that provide access to opioid antagonists approved for the reversal of an opioid overdose.

(5) Linkages to needed services, including mental

health treatment, housing programs, substance use disorder treatment, and other relevant community services.

(6) Individual consultations from a trained employee

tailored to individual needs.

(7) If feasible, a hygienic, separate space for

individuals who need to administer a prescribed injectable medication that can also be used as a quiet space to gather composure in the event of an adverse on-site incident, such as a nonfatal overdose.

(8) If feasible, access to on-site drug adulterant

testing supplies.

(9) If feasible, access to fentanyl test strips to

test for the presence of fentanyl, a fentanyl analog, or a drug adulterant within a controlled substance.

(c) Notwithstanding any provision of the Illinois Controlled Substances Act, the Drug Paraphernalia Control Act, or any other law, no employee or volunteer of or participant in a program established under this Act shall be charged with or prosecuted for possession of any of the following:

(1) Needles, hypodermic syringes, or other drug

consumption paraphernalia obtained from or returned, directly or indirectly, to a program established under this Act.

(2) Residual amounts of a controlled substance

contained in used needles, used hypodermic syringes, or other used drug consumption paraphernalia obtained from or returned, directly or indirectly, to a program established under this Act.

(3) Drug adulterant testing supplies obtained from or

returned, directly or indirectly, to a program established under this Act or a pharmacy, hospital, clinic, or other health care facility or medical office dispensing drug adulterant testing supplies in accordance with Section 10. This paragraph also applies to any employee or customer of a pharmacy, hospital, clinic, or other health care facility or medical office dispensing drug adulterant testing supplies in accordance with Section 10.

(4) Any residual amounts of controlled substances

used in the course of testing the controlled substance to determine the chemical composition and potential threat of the substances obtained for consumption that are obtained from or returned, directly or indirectly, to a program established under this Act. This paragraph also applies to any person using drug adulterant testing supplies procured in accordance with Section 10 of this Act.

In addition to any other applicable immunity or limitation on civil liability, a law enforcement officer who, acting on good faith, arrests or charges a person who is thereafter determined to be entitled to immunity from prosecution under this subsection (c) shall not be subject to civil liability for the arrest or filing of charges.

(d) Prior to the commencing of operations of a program established under this Act, the governmental or nongovernmental organization shall submit to the Illinois Department of Public Health all of the following information:

(1) the name of the organization, agency, group,

person, or entity operating the program;

(2) the areas and populations to be served by the

program; and

(3) the methods by which the program will meet the

requirements of subsection (b) of this Section.

The Department of Public Health may adopt rules to implement this subsection.
(Source: P.A. 102-1039, eff. 6-2-22; 103-980, eff. 1-1-25.)

410 ILCS 710/10

(410 ILCS 710/10)
Sec. 10. Dispensing of drug adulterant testing supplies.

A pharmacist, physician, advanced practice registered nurse, or physician assistant, or the pharmacist's, physician's, advanced practice registered nurse's, or physician assistant's designee, or a  trained overdose responder for an organization enrolled in the Drug Overdose Prevention Program administered by the Department of Human Services, Division of Substance Use Prevention and Recovery may dispense drug adulterant testing supplies to any person. Any drug adulterant testing supplies to be dispensed under this Section must be stored at a licensed pharmacy, hospital, clinic, or other health care facility, at the medical office of a physician, advanced practice registered nurse, or physician assistant, or at the premises of the organization enrolled in the Drug Overdose Prevention Program. Drug adulterant testing supplies shall also be stored so that they are accessible only by pharmacists, physicians, advanced practice registered nurses, or physician assistants employed at the pharmacy, hospital, clinic, or other health care facility or medical office, the designees of the pharmacist, physician, advanced practice registered nurse, or physician assistant, and  trained overdose responders for those organizations enrolled in the Drug Overdose Prevention Program administered by the Department of Human Services, Division of Substance Use Prevention and Recovery. Drug adulterant testing supplies dispensed at a retail store containing a pharmacy under this Section may be dispensed only from the pharmacy department of the retail store. No quantity of drug adulterant testing supplies greater than necessary to conduct 5 assays of substances suspected of containing adulterants shall be dispensed in any single transaction.

(Source: P.A. 102-1039, eff. 6-2-22; 103-115, eff. 1-1-24.)

410 ILCS 710/15

    (410 ILCS 710/15)
    (Text of Section before amendment by P.A. 103-980)
    Sec. 15. Fentanyl test strips.

To further promote harm reduction efforts, a pharmacist or retailer may sell fentanyl test strips over-the-counter to the public to test for the presence of fentanyl, a fentanyl analog, or a drug adulterant within a controlled substance. A county health department may distribute fentanyl test strips at the county health department facility for no fee.

(Source: P.A. 103-336, eff. 1-1-24.)

(Text of Section after amendment by P.A. 103-980)
Sec. 15. Fentanyl test strips.

To further promote harm reduction efforts, a pharmacist or retailer may sell fentanyl test strips over-the-counter to the public to test for the presence of fentanyl, a fentanyl analog, or a drug adulterant within a controlled substance. A county health department may distribute fentanyl test strips for no fee.

(Source: P.A. 103-336, eff. 1-1-24; 103-980, eff. 1-1-25.)

410 ILCS 710/100

(410 ILCS 710/100)

Sec. 100. (Amendatory provisions; text omitted).

(Source: P.A. 101-356, eff. 8-9-19; text omitted.)

410 ILCS 710/200

(410 ILCS 710/200)

Sec. 200. (Amendatory provisions; text omitted).

(Source: P.A. 101-356, eff. 8-9-19; text omitted.)

410 ILCS 710/999

(410 ILCS 710/999)

Sec. 999. Effective date. This Act takes effect upon becoming law.

(Source: P.A. 101-356, eff. 8-9-19.)